Trial reportJournal of the National Cancer Institute2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.
Trial report in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate.Oncotarget · 2017Trial
- Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial.Radiation oncology (London, England) · 2013Trial
- Trial
- Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.Cancer causes & control : CCC · 2011Trial
- Differential expression of cyclins CCNB1 and CCNG1 is involved in the chondrocyte damage of kashin-beck disease.Frontiers in genetics · 2022Article
- Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology.International journal of molecular sciences · 2020Review
- The Mediterranean Diet and Breast Cancer: A Personalised Approach.Healthcare (Basel, Switzerland) · 2019Review
- Role of Key Micronutrients from Nutrigenetic and Nutrigenomic Perspectives in Cancer Prevention.Medicina (Kaunas, Lithuania) · 2019Review
- Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease.Hepatology communications · 2018Review
- Is There a Future for Chemoprevention of Prostate Cancer?Cancer prevention research (Philadelphia, Pa.) · 2016Article
- Review
- Article
- Systems Epidemiology: A New Direction in Nutrition and Metabolic Disease Research.Current nutrition reports · 2013Article
- Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells.Frontiers in oncology · 2013Article
- Article
- Effects of kalsis, a dietary supplement, on bone metabolism in the ovariectomized rats.Journal of osteoporosis · 2012Article
- Selenium regulation of the selenoprotein and nonselenoprotein transcriptomes in rodents.Advances in nutrition (Bethesda, Md.) · 2011Review
- Selenium toxicity but not deficient or super-nutritional selenium status vastly alters the transcriptome in rodents.BMC genomics · 2011Article
- Nutrigenetics, nutrigenomics, and selenium.Frontiers in genetics · 2011Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSecondary analyses of two randomized, controlled phase III trials demonstrated that selenium and vitamin E could reduce prostate cancer incidence. To characterize pharmacodynamic and gene expression effects associated with use of selenium and vitamin E, we undertook a randomized, placebo-controlled phase IIA study of prostate cancer patients before prostatectomy and created a preoperative model for prostatectomy tissue interrogation.
methodsThirty-nine men with prostate cancer were randomly assigned to treatment with 200 microg of selenium, 400 IU of vitamin E, both, or placebo. Laser capture microdissection of prostatectomy biopsy specimens was used to isolate normal, stromal, and tumor cells. Gene expression in each cell type was studied with microarray analysis and validated with a real-time polymerase chain reaction (PCR) and immunohistochemistry. An analysis of variance model was fit to identify genes differentially expressed between treatments and cell types. A beta-uniform mixture model was used to analyze differential expression of genes and to assess the false discovery rate. All statistical tests were two-sided.
resultsThe highest numbers of differentially expressed genes by treatment were 1329 (63%) of 2109 genes in normal epithelial cells after selenium treatment, 1354 (66%) of 2051 genes in stromal cells after vitamin E treatment, and 329 (56%) of 587 genes in tumor cells after combination treatment (false discovery rate = 2%). Validation of 21 representative genes across all treatments and all cell types yielded Spearman correlation coefficients between the microarray analysis and the PCR validation ranging from 0.64 (95% confidence interval [CI] = 0.31 to 0.79) for the vitamin E group to 0.87 (95% CI = 0.53 to 0.99) for the selenium group. The increase in the mean percentage of p53-positive tumor cells in the selenium-treated group (26.3%), compared with that in the placebo-treated group (5%), showed borderline statistical significance (difference = 21.3%; 95% CI = 0.7 to 41.8; P = .051).
conclusionsWe have demonstrated the feasibility and efficiency of the preoperative model and its power as a hypothesis-generating engine. We have also identified cell type- and zone-specific tissue effects of interventions with selenium and vitamin E that may have clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.